...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>診療と新薬 >SWITCH FROM INSULIN THERAPY AND OTHER ORAL HYPOGLYCEMIC AGENTS IN PATIENTS WITH TYPE 2 DIABETES
【24h】

SWITCH FROM INSULIN THERAPY AND OTHER ORAL HYPOGLYCEMIC AGENTS IN PATIENTS WITH TYPE 2 DIABETES

机译：从胰岛素治疗和2型糖尿病患者的口服降糖剂切换

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Aim: Insulin therapy is considered the final option for patients with progressive type 2 diabetes. This study investigated, whether reconverting patients from insulin therapy to oral medicine using thiazolidinedione pioglitazone is possible without further deterioration of glycemic control.Methods: One hundred sixty subjects (112 male and 48 female) aged 61.4 +-13.8 years with an mean insulin dose of 28.3 ±18.7 U/day, mainly using preprandial bolus dose of rapid-acting or ultra-rapid-acting insulin preparations, a duration of insulin therapy of 3.1±1,0 years and an average hemoglobin Ale (Ale) of 9.9 ±1.8% were switched from insulin therapy to combination therapy with pioglitazone and other oral hypoglycemic agents (biguanide, a-glucosidase inhibitor, and glinide).Results: During the observation period (3.2 ±1.3 months),113 patients (70.6%) treated with insulin injections (24.8 +-14.3 U/day), could be successfully switched from insulin therapy to pioglitazone-based oral combination therapy. Their mean Ale significant decreased from 9.9 ± 2.0 to 6.2 ± 0.5%， and all patients could achieve Ale < 7.0%. Although the remaining 47 patients (29.4%) could not be successfully switched, their Ale significant decreased from 10.1+-1.47 to 7.4 +- 0.80/o and their mean insulin dose significantly decreased from 36.7 ± 24.6 to 6.8 +-10.1 U/day. The success rate of switching from insulin to oral agents was significantly higher in the patients treated with non-insulin secretagogues plus glinide, than in the patients treated with non-insulin secretogogues alone. Conclusion: Pioglitazone-based oral combination therapy can efficiently and safely substitute for insulin therapy in patients with type 2 diabetes, treated with mainly preprandial bolus insulin injections.
机译：目的：胰岛素治疗被认为是患有患者2型糖尿病患者的最终选择。本研究调查，是否可以在没有进一步恶化的血糖控制的情况下将从胰岛素治疗的患者重新调整到口腔药物中的口腔药物。方法：一百六十个受试者（112名男性和48名女性），均为平均胰岛素剂量的61.4 + -13.8岁28.3±18.7 U / Day，主要使用预载体剂量的快速作用或超快速作用胰岛素制剂，持续时间胰岛素治疗3.1±1,0岁和平均血红蛋白αLE（α）为9.9±1.8％从胰岛素治疗切换到与吡格列酮和其他口服降糖剂（双胍，A-葡糖苷酶抑制剂和龙笑转录）的联合治疗。结果：在观察期（3.2±1.3个月），113名患者（70.6％）用胰岛素注射治疗（24.8 + -14.3 U /日），可以从胰岛素治疗成功转化为基于吡格列酮的口腔组合疗法。它们的平均啤酒显着降低了9.9±2.0至6.2±0.5％，所有患者均可达到啤酒<7.0％。虽然剩余的47名患者（29.4％）不能成功转换，但它们的啤酒显着降低至7.4±0.80 / O至7.4±0.80 / O，其平均胰岛素剂量从36.7±24.6至6.8±24.6％下降到6.8±10.1 u /日。在用非胰岛素促分泌术治疗的患者中，胰岛素对口服胰岛素的切换成功率明显高于单纯胰岛素分泌释放期间的患者。结论：基于吡格列酮的口腔组合疗法可以有效，安全地替代2​​型糖尿病患者的胰岛素治疗，主要用预载体推注胰岛素注射治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号